Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cyclophosphamide + melphalan + etoposide
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This high-dose combination chemotherapy regimen, followed by autologous progenitor cell transplantation (ASCT), was investigated by the National Cancer Institute (NCI) for the treatment of stage IIIB inflammatory breast cancer (IBC). The protocol involves an induction phase with paclitaxel and cyclophosphamide, followed by a consolidation phase using high-dose melphalan and etoposide. Paclitaxel acts as a microtubule stabilizer, preventing the disassembly of tubulin and arresting the cell cycle. Cyclophosphamide and melphalan are nitrogen mustard alkylating agents that form DNA cross-links, leading to cell death. Etoposide is a topoisomerase II inhibitor that induces double-stranded DNA breaks. Because the high-dose consolidation phase is severely myelosuppressive, autologous progenitor cells are reinfused to rescue and restore the patient's hematopoietic system.
- Brand names
- TaxolCytoxanAlkeranVepesidEtopophos
- Other names
- High-Dose Chemotherapy and Autologous Transplant for Inflammatory Breast Cancer
Beyond the preview
Go deeper on paclitaxel + cyclophosphamide + melphalan + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cyclophosphamide + melphalan + etoposide.